TXNIP and diabetes mellitus: Promising results have been obtained in experimental models of diabetes with anti-TXNIP agents, such as S-Equol (Chen et al., 2020), SRI-37330 (Thielen et al., 2020), MiR-17-5p (Liu et al., 2021), and fluoromethyl ketone (FMK) (Han et al., 2019).